Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Vox Sang ; 109(1): 91-4, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25833739

RESUMO

Platelets are prophylactically transfused to patients receiving myeloablative chemotherapy. The trigger can be adapted if a patient has risk factors for bleeding. We performed an international survey to quantify differences in transfusion policies. While platelet counts are most important, bleeding, fever, use of anticoagulants and invasive procedures also determine transfusion strategies. The largest variation of triggers was observed for lumbar punctures and removal of central venous catheters.


Assuntos
Transfusão de Plaquetas/efeitos adversos , Adulto , Idoso , Anticoagulantes/uso terapêutico , Febre/etiologia , Guias como Assunto , Neoplasias Hematológicas/patologia , Hemorragia/prevenção & controle , Humanos , Pessoa de Meia-Idade , Contagem de Plaquetas , Fatores de Risco , Inquéritos e Questionários , Trombocitopenia/prevenção & controle
2.
Transfus Med ; 22(6): 426-31, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23036067

RESUMO

BACKGROUND: The reported percentage of haemato-oncological patients experiencing bleeding complications is highly variable, ranging from 5 to 70%, posing a major problem for comparison of clinical platelet transfusion trials using bleeding complications as a primary endpoint. In a pilot study we assessed the impact of the design of scoring of bleeding on the percentage of patients with WHO grade 2 or higher bleeding grades. STUDY DESIGN AND METHODS: We performed a prospective, observational study using a rigorous bleeding observation system in thrombocytopenic patients with haemato-oncological disorders. Endpoints of the study were the percentage of patients and days with bleeding WHO grade ≥ 2 comparing designs in which skin bleeding represent a continuation of a previous bleed or a new bleed. RESULTS: In four participating hospitals 64 patients suffering 870 evaluable thrombocytopenic days (platelet count < 80 × 10(9) L(-1)) were included. At least one episode of bleeding grade ≥ 2 occurred in 36 patients (56%). Most grade 2 bleeding complications occurred mucocutaneously. The percentage of days with bleeding of grade ≥ 2 was 16% but decreases to 8% when only newly developed skin bleeding was included. CONCLUSION: Rigorous daily observation results in a bleeding incidence that is comparable to recent reportings applying the same method. The results of this study show that censoring for stable skin bleeding has a profound effect on bleeding incidence per day. The clinical relevance of rigorous or clinically judged bleeding scores as an endpoint remains to be defined.


Assuntos
Neoplasias Hematológicas , Hemorragia , Transfusão de Plaquetas , Adulto , Idoso , Feminino , Neoplasias Hematológicas/sangue , Neoplasias Hematológicas/complicações , Neoplasias Hematológicas/epidemiologia , Neoplasias Hematológicas/terapia , Hemorragia/sangue , Hemorragia/epidemiologia , Hemorragia/etiologia , Hemorragia/terapia , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Contagem de Plaquetas , Estudos Prospectivos , Trombocitopenia/sangue , Trombocitopenia/epidemiologia , Trombocitopenia/etiologia , Trombocitopenia/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA